aod9604 randomized trial obesity Clinical safety and tolerability of in treatment AOD-9604 Clinical Trial Results &
AOD 9604 Clinical Trial Results & FDA Status (2026) Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin 4 receptor agonist, led to significantly greater reductions in body mass index and hunger than placebo at 52 weeks. AOD 9604 5mg The effects of 14 day infusion of saline (control), AOD9604 (250 Download Scientific Diagram AOD 9604 AOD9604 Peptide for Fat Loss: Mechanism, Benefits & Risks Explained
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12




